Clinical trial
Celecoxib Treatment for Lung Cancer
NCT00108186 · US Department of Veterans Affairs, U.S. Fed · Withdrawn
Key facts
| NCT number | NCT00108186 |
|---|---|
| Title | Celecoxib Treatment for Lung Cancer |
| Official title | Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer |
| Lead sponsor | US Department of Veterans Affairs, U.S. Fed |
| Collaborators | University of California, Los Angeles City of Hope Medical Center |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 0 |
| Start date | Oct 1, 2004 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Apr 15, 2005 |
| Last update posted | Oct 29, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: